Parthenolide cytotoxicity increased in combination with arsenic trioxode in mt2 lymphoma cells
- سال انتشار: 1396
- محل انتشار: سومین سمپوزیوم بین المللی سرطان نسترن
- کد COI اختصاصی: NASTARANCANSER03_209
- زبان مقاله: انگلیسی
- تعداد مشاهده: 396
نویسندگان
Cancer Molecular Pathology Research Center, Department Of Hematology And Blood Bank,Faculty Of Medicine, Mashhad University Of Medical Sciences, Iran
Inflammation And Inflammatory Diseases Research Center, Faculty Of Medicine, Mashhad University Of Medical Sciences, Mashhad, Iran
Inflammation And Inflammatory Diseases Research Center, Faculty Of Medicine, Mashhad University Of Medical Sciences, Mashhad, Iran
Cell And Molecular Biotechnology Research Group, Institute Of Biotechnology, Ferdowsi University Of Mashhad,Mashhad, Iran
چکیده
Adult T-cell leukemia/lymphoma (ATLL) is a peripheral T-cell lymphoma caused by human T-cell leukemia/lymphoma virus type1 (HTLV-1). Iran, especially Khorasan province, is known as one of theendemic regions for HTLV-1. Despite advances in the treatment of ATLL, the average survival rate of this malignancy is low. Parthenolide is a sesquiterpene lactone with broad-spectrum anticancer andantiproliferative activities. To introduce more effective anticancer strategies against ATLL, here we investigate whether parthenolide could enhance the efficacy of arsenic trioxide, a chemical drug prescribed for ATLL. In this regard, at first MT-2 cells, an ATLL cell line, were treated with increasing concentrations of parthenolide (1.25, 2.5 and 5 μg/ml) and arsenic (1, 2, 4 and 8 μg/ml) for 24, 48 and 72 h, and the IC50 value of drugs was determined. Then, cells were treated with a combination of parthenolide (1 and 2 μg/ml) and arsenic (1 and 2 μg/ml) for 72 h. Finally, the viability of cells was measured by Alamar blue test, and apoptosis was determined by PI staining and flow cytometry. Obtained results indicated that 1 μg/ml parthenolide increased the toxicity of 2 μg/ml arsenic, and therefore, had synergic effects with this anticancer drug. In conclusion, current findings suggest that combinatorial use of parthenolide and arsenic can be helpful in ATLL treatment.کلیدواژه ها
Blood Cancer, Cell and Cancer, Cancer Treatment and Management, Targeted Cancer Therapy, Drugs and Cancerاطلاعات بیشتر در مورد COI
COI مخفف عبارت CIVILICA Object Identifier به معنی شناسه سیویلیکا برای اسناد است. COI کدی است که مطابق محل انتشار، به مقالات کنفرانسها و ژورنالهای داخل کشور به هنگام نمایه سازی بر روی پایگاه استنادی سیویلیکا اختصاص می یابد.
کد COI به مفهوم کد ملی اسناد نمایه شده در سیویلیکا است و کدی یکتا و ثابت است و به همین دلیل همواره قابلیت استناد و پیگیری دارد.